KR102995415B1 - 미토콘드리아 질환을 표적으로 하는 유사체 - Google Patents
미토콘드리아 질환을 표적으로 하는 유사체Info
- Publication number
- KR102995415B1 KR102995415B1 KR1020217018416A KR20217018416A KR102995415B1 KR 102995415 B1 KR102995415 B1 KR 102995415B1 KR 1020217018416 A KR1020217018416 A KR 1020217018416A KR 20217018416 A KR20217018416 A KR 20217018416A KR 102995415 B1 KR102995415 B1 KR 102995415B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- ischemia
- delete delete
- acid
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781156P | 2018-12-18 | 2018-12-18 | |
| US62/781,156 | 2018-12-18 | ||
| PCT/US2019/062284 WO2020131283A1 (en) | 2018-12-18 | 2019-11-19 | Analogs that target mitochondrial diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210093958A KR20210093958A (ko) | 2021-07-28 |
| KR102995415B1 true KR102995415B1 (ko) | 2026-07-23 |
Family
ID=71101584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217018416A Active KR102995415B1 (ko) | 2018-12-18 | 2019-11-19 | 미토콘드리아 질환을 표적으로 하는 유사체 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12252554B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3898653A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7606966B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102995415B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113383005A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019401254B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3123610A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284014A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020131283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113544138B (zh) | 2018-12-18 | 2024-10-29 | 隐形生物治疗公司 | 线粒体靶向肽 |
| WO2020131283A1 (en) | 2018-12-18 | 2020-06-25 | Stealth Biotherapeutics Corp. | Analogs that target mitochondrial diseases |
| US20240197623A1 (en) * | 2021-04-07 | 2024-06-20 | Stealth Bio Therapeutics Inc. | Silica-based formulations of therapeutic oliogpeptides and peptidomimetics |
| KR102876070B1 (ko) * | 2023-02-08 | 2025-10-24 | 웰펩 주식회사 | 신규 펩티도미메틱을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물 |
| WO2026151834A1 (en) | 2025-01-09 | 2026-07-16 | Stealth Biotherapeutics Inc. | Compounds for use in medical management of subjects with muscular dystrophy |
| WO2026151846A1 (en) | 2025-01-09 | 2026-07-16 | Stealth Biotherapeutics Inc. | Compositions for use in the treatment of heart failure, idiopathic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or hypertensive cardiomyopathy |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004070054A2 (en) | 2003-02-04 | 2004-08-19 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| US20110118441A1 (en) | 2010-12-14 | 2011-05-19 | Xueyun Gao | Synthesis of Highly Fluorescent Peptide-Metallic Nanoclusters as Bio-probes |
| WO2011116007A1 (en) | 2010-03-15 | 2011-09-22 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| US20150010588A1 (en) | 2012-02-23 | 2015-01-08 | Cornell University | Aromatic-cationic peptides and uses of same |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787331A1 (en) * | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
| CN103249423A (zh) | 2010-07-09 | 2013-08-14 | 康肽德生物医药技术有限公司 | 预防或治疗缺血/再灌注损伤之后无复流的方法 |
| EP3108975A1 (en) | 2011-03-24 | 2016-12-28 | Cornell University | Aromatic-cationic peptides and uses of same |
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CA2916492A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Biotherapeutics Corp | Peptide therapeutics and methods for using same |
| CN106459169A (zh) | 2014-03-03 | 2017-02-22 | 康德生物医疗技术公司 | 药学上相关的芳香族阳离子肽 |
| WO2015183984A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
| WO2016144352A2 (en) | 2015-03-11 | 2016-09-15 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same |
| WO2017093897A1 (en) | 2015-11-30 | 2017-06-08 | Peter Schiller | Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome |
| CA3010321A1 (en) | 2015-12-31 | 2017-07-06 | Scott Duncan | Therapeutic compositions including peptides and uses thereof |
| US20190276494A1 (en) | 2016-05-19 | 2019-09-12 | Stealth Biotherapeutics Corp. | Compositions and methods for the prevention and treatment of mitochondrial myopathies |
| WO2018186404A1 (ja) * | 2017-04-03 | 2018-10-11 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子及び電子機器 |
| WO2018223032A1 (en) | 2017-06-02 | 2018-12-06 | Stealth Biotherapeutics Corp. | Crystalline salt forms of sbt-20 |
| US20200361987A1 (en) | 2017-11-15 | 2020-11-19 | Stealth Biotherapeutics Corp. | Deuterated tetrapeptides that target mitochondria |
| CN113544138B (zh) | 2018-12-18 | 2024-10-29 | 隐形生物治疗公司 | 线粒体靶向肽 |
| WO2020131283A1 (en) | 2018-12-18 | 2020-06-25 | Stealth Biotherapeutics Corp. | Analogs that target mitochondrial diseases |
-
2019
- 2019-11-19 WO PCT/US2019/062284 patent/WO2020131283A1/en not_active Ceased
- 2019-11-19 JP JP2021533856A patent/JP7606966B2/ja active Active
- 2019-11-19 US US17/414,168 patent/US12252554B2/en active Active
- 2019-11-19 KR KR1020217018416A patent/KR102995415B1/ko active Active
- 2019-11-19 CA CA3123610A patent/CA3123610A1/en active Pending
- 2019-11-19 CN CN201980083870.0A patent/CN113383005A/zh active Pending
- 2019-11-19 EP EP19900766.7A patent/EP3898653A4/en active Pending
- 2019-11-19 AU AU2019401254A patent/AU2019401254B2/en active Active
-
2021
- 2021-06-15 IL IL284014A patent/IL284014A/en unknown
-
2025
- 2025-02-10 US US19/049,634 patent/US20260008810A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004070054A2 (en) | 2003-02-04 | 2004-08-19 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| WO2011116007A1 (en) | 2010-03-15 | 2011-09-22 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| US20110118441A1 (en) | 2010-12-14 | 2011-05-19 | Xueyun Gao | Synthesis of Highly Fluorescent Peptide-Metallic Nanoclusters as Bio-probes |
| US20150010588A1 (en) | 2012-02-23 | 2015-01-08 | Cornell University | Aromatic-cationic peptides and uses of same |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113383005A (zh) | 2021-09-10 |
| AU2019401254A1 (en) | 2021-06-24 |
| WO2020131283A1 (en) | 2020-06-25 |
| EP3898653A1 (en) | 2021-10-27 |
| KR20210093958A (ko) | 2021-07-28 |
| US20220041654A1 (en) | 2022-02-10 |
| AU2019401254B2 (en) | 2025-05-01 |
| CA3123610A1 (en) | 2020-06-25 |
| US20260008810A1 (en) | 2026-01-08 |
| US12252554B2 (en) | 2025-03-18 |
| JP7606966B2 (ja) | 2024-12-26 |
| EP3898653A4 (en) | 2022-08-24 |
| JP2022514241A (ja) | 2022-02-10 |
| IL284014A (en) | 2021-08-31 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| F13 | Ip right granted in full following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |